Navigation Links
Echo Therapeutics Announces Second Quarter 2011 Financial Results
Date:8/12/2011

t loss per common share for the first half of 2011 was approximately $6.5 million, or ($0.26) per share, compared to a net loss of $2.4 million, or ($0.09) per share, in the prior year.  The company completed the quarter with cash of approximately $3.2 million.

About Echo TherapeuticsEcho Therapeutics is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units.  Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking StatementsThe statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's and its partners' ongoing studies, including the safety and efficacy of Echo's Symphony tCGM and Prelude SkinPrep Systems, the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM and Prelude SkinPrep Systems, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM and Prelude SkinPrep Systems, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and
'/>"/>

SOURCE Echo Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Halozyme Therapeutics to Present at the Wedbush 2011 Global Healthcare Conference on August 17
2. Prime Therapeutics Announces Pharmacy Offering with Guaranteed Net Spend Per Prescription
3. Echo Therapeutics Unveils Symphony tCGM Demonstration Video
4. Orexigen® Therapeutics Reports Second Quarter Ended June 30, 2011 Financial Results
5. Echo Therapeutics Announces Multiple Patents and Trademark Grants
6. Nektar Therapeutics Reports Second Quarter 2011 Financial Results
7. Silence Therapeutics Receives Notice of Allowance for New U.S. Patent Covering Novel Small Interfering RNA (siRNA) Delivery Technology
8. Prefilled Syringes: Devices, Therapeutics, Players, Markets and Prospects
9. Dry Powder Inhalation: Devices, Drugs, Therapeutics, Markets and Forecasts
10. Argos Therapeutics Files Registration Statement for Proposed Initial Public Offering
11. Cell Therapeutics, Inc. (CTI) Reports Reduction in Operating Expenses and Net Losses for Second Quarter and First Half 2011 Compared to 2010, and Advances In Bringing Pixantrone to Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... Intarcia Therapeutics, Inc. today announced successful top-line results ... for ITCA 650 (exenatide, delivered continuously once or twice ... trial, FREEDOM-1, was a placebo-controlled, double-blind phase 3 clinical ... 650 in patients with type 2 diabetes against placebo. ... to placebo for both 40 mcg and 60 mcg ...
(Date:10/1/2014)... , Oct. 1, 2014 ... now available. Interested parties can learn about ... Cardinal Health is supporting the health care ... http://cardinalhealth.com/annualreport . Photo- http://photos.prnewswire.com/prnh/20140930/149504-INFO ... summary financials and the chief executive officer,s ...
(Date:10/1/2014)...  Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a ... used to develop and produce enzymes and other ... industrial enzymes industries, today announced the receipt of ... commercial scale production of Abengoa,s proprietary cellulase enzymes, ... Abengoa,s license agreement with Dyadic. ...
Breaking Medicine Technology:Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 2Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 5Cardinal Health 2014 Digital Report to Shareholders Now Available 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 3
... the worldwide leader in handheld x-ray technologies, has been ... Edison Best New Product Awards™. The winners were announced ... ballroom in New York City.  The NOMAD® Handheld X-ray ... Medical Handheld or Miniaturized Devices Segment. ...
... PRA International, a leading Clinical Research Organization, announces that ... will speak at the World Drug Safety Congress being held ... host an exhibit at booth #2. Dr. ... first breakout stream, "Operational Safety," on 13 April at 1:50 ...
Cached Medicine Technology:NOMAD by Aribex Receives Edison Best New Product Award 2PRA International Experts to Speak at Drug Safety Conference 2
(Date:10/1/2014)... from the University of Adelaide have developed a model ... a good outcome from treatment - from their very ... a range of factors, including clinical symptoms, cognitive abilities, ... the patient,s blood. , Speaking in the lead up ... Head of Psychiatry , Professor Bernhard Baune ...
(Date:10/1/2014)... research co-funded by the Engineering and Physical Sciences ... of the UK,s vital industrial control systems which ... electricity grid, and the rail network. , ... from hackers or malware infiltrating the systems behind ... Institute in Trustworthy Industrial Control Systems (RITICS), based ...
(Date:10/1/2014)... 01, 2014 Marriagelifeinsurance.com has released ... insurance for retired couples. , Senior citizens can ... security for their loved ones. A joint policy is ... persons pass away. , Life insurance can be ... insurance can even be purchased online, as the application ...
(Date:10/1/2014)... October 01, 2014 Phoseon Technology, the ... continues to expand the business worldwide. This rapid growth ... additional capacity for manufacturing efforts. The company has experienced ... five years and expects this growth to continue in ... technology gains worldwide adoption. , “We are very ...
(Date:10/1/2014)... Beverly Hills, California (PRWEB) October 01, 2014 ... relationship expert, Dr. Kathleen Mojas is celebrating 20 years ... she has assisted hundreds of people to achieve greater ... released an important list of warning signs and suggestions ... relationship. , Dr. Mojas explains: “Believe it or ...
Breaking Medicine News(10 mins):Health News:Predicting the future course of psychotic illness 2Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:Elderly Life Insurance - Find Life Insurance for Retired Couples! 2Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3
... eye mainly during the surgical treatment of retinal hemorrhages or ... the detached retina to the wall of the eye. There ... during airplane travel, at high altitudes, or under nitrous oxide ... risk remains present for weeks after the surgical procedure. , ...
... ATLANTA, Feb. 25 CIBER, Inc. ... and implemented a service-oriented,architecture (SOA)-based software application ... for Disease Control and Prevention (CDC). CDCAS,reliably, ... and public,health organizations of disease outbreaks, bioterrorism ...
... small-diameter implants expanded more than 30% in 2007, ... according to Millennium Research Group, ... shows that small-diameter (less than or equal to 3.0 mm),dental ... implants are growing at a faster rate than those of ...
... Park have discovered that Normal Human Bronchial Epithelial (NHBE) ... the high end of plasma zinc attainable by oral ... arrest and DNA damage-induced gene (Gadd45) mRNA and protein ... research, published in the March 08 issue of the ...
... February 24, 2008: With a deep understanding of healthcare ... a global medical publisher, Elsevier is broadening its efforts ... (CDS) tools that help providers make optimal decisions at ... acquired CPM Resource Center, a provider of interactive nursing ...
... who examined blood test records in a survey of over ... found thousands of cases of probable undiagnosed diabetes. This could ... in UK. , The research is published in the ... was led by Dr Tim Holt of the University of ...
Cached Medicine News:Health News:CDC Uses CIBER-Built Solution to Alert Public Health Officials and Public Health Departments 2Health News:CDC Uses CIBER-Built Solution to Alert Public Health Officials and Public Health Departments 3Health News:CDC Uses CIBER-Built Solution to Alert Public Health Officials and Public Health Departments 4Health News:Small-Diameter Dental Implants Increasingly Popular In the US 2Health News:High zinc status in lung cells slows growth and induces DNA damage-induced gene expression 2Health News:High zinc status in lung cells slows growth and induces DNA damage-induced gene expression 3Health News:Elsevier enhances clinical decision making with suite of Clinical Decision Support solutions 2Health News:Elsevier enhances clinical decision making with suite of Clinical Decision Support solutions 3Health News:Elsevier enhances clinical decision making with suite of Clinical Decision Support solutions 4Health News:GP's databases could identify tens of thousands with undiagnosed diabetes in UK 2
The Vitatron Excellence S+ lead series are endocardial leads providing excellent reliability and optimal pacing characteristics....
CapSure SP Novus endocardial, tined pacing leads provide the stable, low pacing thresholds and large sensing potentials already proven with CapSure SP steroid-eluting leads but within an even smaller...
Bipolar Atrial "J" Lead...
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
Medicine Products: